2. **(Amended)** The RNA molecule of Claim 1, which is replication-competent in the target cell.

3. **(Amended)** The RNA molecule of Claim 1, wherein in the virus genome parts of its coding sequence have been replaced by the at least one foreign gene.

4. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its capsid proteins VP1-VP4 have been replaced by the at least one foreign gene.

5. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its protease 2A and/or 3C have been modified such that there is no cytotoxicity for the target cell.

6. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its helicase 2C have been replaced by the at least one foreign gene.

7. **(Amended)** The RNA molecule of Claim 2, wherein in the virus genome the sequences of its protein 2B have been replaced by the at least one foreign gene.

9. **(Amended)** A recombinant, infectious virion which is derived from Coxsackie Virus group B, preferably serotype B3, and whose genome comprises the RNA molecule of Claim 1.

10. **(Amended)** The virion of Claim 9, which corresponds in its structural proteins to a Coxsackie virus group B, preferably serotype B3.

12. **(Amended)** A vector plasmid having at least one DNA sequence which codes for the RNA molecule of Claim 1, and having a promoter located in front of the DNA sequence.

13. **(Amended)** A helper construct for complementing the coding sequences replaced in the RNA molecule of Claim 1.

14. **(Amended)** The helper construct of Claim 13, which is a helper plasmid which codes for at least one of the replaced sequences in a translatable manner.

15. **(Amended)** The helper construct of Claim 13, which is a viral vector which codes for at least one of the replaced sequences in a translatable manner.

16. **(Amended)** The helper construct of Claim 13, which is a helper cell which has been transfected stably with helper DNA coding for at least one of the replaced sequences.

21. **(Amended)** A kit, comprising the vector plasmid of Claim 12 and the helper construct of Claim 13.

22. **(Amended)** A DNA molecule having at least one sequence section coding for the RNA molecule of Claim 1.

25. **(Amended)** A therapeutic composition comprising the RNA molecule of Claim 1.

27. **(Amended)** A therapeutic composition with the virion of claim 9.

28. **(Amended)** A DNA construct which codes for the RNA molecule of Claim 1 and which persists and transcribes in a target cell but preferably does not replicate in the latter.

29. **(Amended)** A recombinant virus, preferably adeno- or retrovirus, which codes for the RNA molecule of Claim 1 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.

Please, add new Claims:

33. **(New)** The RNA molecule of claim 2, wherein in the virus genome the sequences of its protease 2A and/or 3C have been replaced by the at least one foreign gene.

34. **(New)** A recombinant, infectious virion which is derived from Coxsackie Virus group B, preferably serotype B3, and whose genome comprises the RNA molecule of Claim 2.

35. **(New)** A vector plasmid having at least one DNA sequence which codes for the RNA molecule of Claim 2, and having a promoter located in front of the DNA sequence.

36. **(New)** A helper construct for complementing the coding sequences replaced in the RNA molecule of Claim 2.

37. **(New)** A DNA molecule having at least one sequence section coding for the RNA molecule of Claim 2.

38. **(New)** A therapeutic composition comprising the RNA molecule of Claim 2.

39. **(New)** A DNA construct which codes for the RNA molecule of Claim 2 and which persists and transcribes in a target cell but preferably does not replicate in the latter.

40. **(New)** A recombinant virus, preferably adeno- or retrovirus, which codes for the RNA molecule of Claim 2 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.

REMARKS

An Abstract has been added to the Specification. Claims 8, 11, 17, 18, 19, 20, 24, 31, and 32 have been cancelled without prejudice. Claims 2-7, 9, 10, 12-16, 21, 22, 25, 27, 28, and 29 have been amended to more precisely claim the invention according to conventional practice before the United States Patent and Trademark Office. New Claims 33 – 40 have been added. Support for new Claims 33 –40 can be found in original Claims. As a result Claims 1-7, 9, 10, 12-16, 21, 22, 23, 25-30, and 33 - 40 are presented for examination. No new matter is being